Questions Raised About Performance Of Pfizer’s COVID-19 Pill

questions_raised_about_performance_of_pfizers_covid_19_pill.jpg /

New questions are emerging about the performance of Pfizer’s COVID-19 pill, including why a small number of patients appear to relapse after taking the drug.   The Associated Press reports that Paxlovid has become the go-to option in the US against COVID-19 because of its at-home convenience and impressive results in heading off severe disease.   The drug was authorised in December for adults at high risk of severe COVID-19 and the US government has spent more than $10 billion to purchase enough pills to treat 20 million people.   But doctors have started reporting rare cases of patients whose symptoms returned several days after completing Paxlovid’s five-day regimen of pills.    That has prompted questions about whether those patients are still contagious and should receive a second course of Paxlovid.